Cargando…
Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology
BACKGROUND AND OBJECTIVES: Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID‐19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is not transmissible by transfusion, but bloodborne pathogens...
Autores principales: | Yonemura, Susan, Hartson, Lindsay, Dutt, Taru S., Henao‐Tamayo, Marcela, Goodrich, Raymond, Marschner, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251479/ https://www.ncbi.nlm.nih.gov/pubmed/33835489 http://dx.doi.org/10.1111/vox.13108 |
Ejemplares similares
-
Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
por: Ragan, Izabela, et al.
Publicado: (2020) -
Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light
por: Ragan, Izabela K., et al.
Publicado: (2023) -
Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment
por: Keil, Shawn D., et al.
Publicado: (2020) -
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
por: Keil, Shawn D., et al.
Publicado: (2015) -
Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies
por: Cardoso, Marcia, et al.
Publicado: (2023)